After the markets closed Friday, Amgen and AstraZeneca announced that their top psoriasis contender, brodalumab, scored a win in Phase III, with a large majority of patients in both dosage arms clearing the bar on a standard measure for efficacy.

…read more

Source: Amgen, AstraZeneca score a PhIII psoriasis success with brodalumab


0 No comments